Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2016 2
2018 1
2019 2
2021 6
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Sjögren's syndrome: one year in review 2022.
Manfrè V, Chatzis LG, Cafaro G, Fonzetti S, Calvacchi S, Fulvio G, Navarro Garcia IC, La Rocca G, Ferro F, Perricone C, Bartoloni E, Baldini C. Manfrè V, et al. Clin Exp Rheumatol. 2022 Dec;40(12):2211-2224. doi: 10.55563/clinexprheumatol/43z8gu. Epub 2022 Dec 20. Clin Exp Rheumatol. 2022. PMID: 36541236 Free article. Review.
B-cells hyperactivation is supported by genetic risk factors, T-cell dependent and independent mechanisms, and the presence of different pathogenic B-cell subsets must be reminded.Many aspects have been investigated in the last year regarding genetic and epigenetics, B- and T-cel …
B-cells hyperactivation is supported by genetic risk factors, T-cell dependent and independent mechanisms, and the presence of different pat …
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.
Belluomini L, Calvetti L, Inno A, Pasello G, Roca E, Vattemi E, Veccia A, Menis J, Pilotto S. Belluomini L, et al. Front Oncol. 2022 Apr 14;12:840783. doi: 10.3389/fonc.2022.840783. eCollection 2022. Front Oncol. 2022. PMID: 35494084 Free PMC article. Review.
Innovative treatment strategies and combinations are currently under investigation to further improve the expected prognosis of patients with SCLC. Following the recent therapeutic innovations, we have reviewed the available literature data about SCLC management, with a fo …
Innovative treatment strategies and combinations are currently under investigation to further improve the expected prognosis of patients wit …
Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: A systematic review and expert opinion.
Cai T, Novelli A, Tascini C, Stefani S. Cai T, et al. Int J Antimicrob Agents. 2023 Dec;62(6):106983. doi: 10.1016/j.ijantimicag.2023.106983. Epub 2023 Sep 24. Int J Antimicrob Agents. 2023. PMID: 37748624 Free article. Review.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recently reduced the susceptibility breakpoint for E. coli from 32 mg/L to 8 mg/L regarding FT used for uUTIs. ...
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recently reduced the susceptibility breakpoint for E. coli fr …
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C, Muthusamy B, Spitaleri G, Del Signore E, Pennell NA. Catania C, et al. Clin Lung Cancer. 2022 Mar;23(2):108-115. doi: 10.1016/j.cllc.2021.11.003. Epub 2021 Nov 11. Clin Lung Cancer. 2022. PMID: 34952792 Review.
However, the rate of local and metastatic recurrences following surgery alone is high, especially in NSCLC patients with N2 lymph node involvement. A recent American study showed that 60% of lung cancers are diagnosed in an advanced stage, and less than 20% are diagnosed i …
However, the rate of local and metastatic recurrences following surgery alone is high, especially in NSCLC patients with N2 lymph node invol …
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. Caparello C, et al. World J Gastroenterol. 2016 Aug 21;22(31):6987-7005. doi: 10.3748/wjg.v22.i31.6987. World J Gastroenterol. 2016. PMID: 27610011 Free PMC article. Review.
However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase III trial showing an improved outcome over g …
However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many effor …
Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.
Colella G, Fazioli F, Gallo M, De Chiara A, Apice G, Ruosi C, Cimmino A, de Nigris F. Colella G, et al. Int J Mol Sci. 2018 Feb 21;19(2):615. doi: 10.3390/ijms19020615. Int J Mol Sci. 2018. PMID: 29466296 Free PMC article. Review.
The main advantage of 3D cultures from tumor cells or biopsy is that they provide patient-specific models of solid tumors, and they overcome some limitations of traditional 2D monolayer cultures by reflecting cell heterogeneity, native histologic architectures, and cell-extracell …
The main advantage of 3D cultures from tumor cells or biopsy is that they provide patient-specific models of solid tumors, and they overcome …
Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy.
Maria B, Antonella V, Michela R, Silvana G, Anita S, Anna Maria A, Chiara D, Paolo M. Maria B, et al. Ther Adv Med Oncol. 2016 Nov;8(6):450-459. doi: 10.1177/1758834016659825. Epub 2016 Jul 25. Ther Adv Med Oncol. 2016. PMID: 27800033 Free PMC article. Review.
Failure of chemical therapy has always been attributed to an intact blood-brain barrier and acquired drug resistance by renal cancer cells. Recent studies have demonstrated objective responses with TT in a variety of cancer types, including renal cancer. ...
Failure of chemical therapy has always been attributed to an intact blood-brain barrier and acquired drug resistance by renal cancer cells. …
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.
Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, Gregorc V. Mirabile A, et al. Cancers (Basel). 2019 Mar 1;11(3):296. doi: 10.3390/cancers11030296. Cancers (Basel). 2019. PMID: 30832285 Free PMC article. Review.
The advent of immune checkpoint inhibitors gave rise to a new era in oncology and general medicine. The increasing use of programmed death-1 (PD-1) inhibitors in non-small cell lung cancer and in other malignancies means clinicians have to face up to new challenges in mana …
The advent of immune checkpoint inhibitors gave rise to a new era in oncology and general medicine. The increasing use of programmed …
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G. Tucci M, et al. Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7. Cancer Treat Rev. 2019. PMID: 30738364 Free article. Review.
Five new therapeutic agents (abiraterone acetate, enzalutamide, cabazitaxel, radium-223, sipuleucel-T), all able to improve overall survival, have been introduced in the management of metastatic castration-resistant prostate cancer. Moreover, recent evidences showed that a …
Five new therapeutic agents (abiraterone acetate, enzalutamide, cabazitaxel, radium-223, sipuleucel-T), all able to improve overall survival …
Decision making and treatment options in endourology post-coronavirus disease 2019 - adapting to the future.
Proietti S, Basulto-Martinez M, Pavia MP, Luciani L, Gaboardi F, Giusti G. Proietti S, et al. Curr Opin Urol. 2021 Mar 1;31(2):109-114. doi: 10.1097/MOU.0000000000000857. Curr Opin Urol. 2021. PMID: 33394610
PURPOSE OF REVIEW: To describe and critically discuss the most recent evidence regarding stone management during the coronavirus disease 2019 (COVID-19) and post-COVID-19 era. RECENT FINDINGS: There is a need to plan for resuming the normal elective stone sur …
PURPOSE OF REVIEW: To describe and critically discuss the most recent evidence regarding stone management during the coronavirus dise …
18 results